Holen Sie sich die Stockscreener-App
2.18
0.93%
0.02
Schlusskurs vom Vortag:
$2.16
Offen:
$2.17
24-Stunden-Volumen:
6,140
Relative Volume:
0.29
Marktkapitalisierung:
$15.30M
Einnahmen:
$1.34M
Nettoeinkommen (Verlust:
$-13.49M
KGV:
-0.1757
EPS:
-12.4093
Netto-Cashflow:
$-3.07M
1W Leistung:
+0.93%
1M Leistung:
+0.00%
6M Leistung:
-15.83%
1J Leistung:
+0.00%
1-Tages-Spanne:
$2.12
$2.23
1-Wochen-Bereich:
$2.12
$2.2744
52-Wochen-Spanne:
$1.75
$12.87
Vyome Holdings Inc Stock (HIND) Company Profile
Firmenname
Vyome Holdings Inc
Sektor
Branche
Telefon
949-429-6680
Adresse
1001 CALLE AMANECER, SAN CLEMENTE
Compare HIND vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HIND
Vyome Holdings Inc
|
2.18 | 15.58M | 1.34M | -13.49M | -3.07M | -12.41 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Vyome Holdings Inc Aktie (HIND) Neueste Nachrichten
VYOME HOLDINGS ($HIND) Releases Q2 2026 Earnings - quiverquant.com
Vyome Holdings Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Vyome Holdings (HIND) posts higher H1 2026 loss as R&D spending grows - Stock Titan
Vyome Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Vyome Holdings Ord Shs (HIND) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
Vyome Holdings Inc expected to post a loss of 19 cents a shareEarnings Preview - TradingView
HIND Q2'26 Earnings: EPS estimate is (0.19) USD - TradingView
Vyome Holdings, Inc. Revenue Breakdown – NASDAQ:HIND - TradingView
Vyome Holdings (HIND) Slides 2.37%: Support and Resistance Levels in FocusSafe Entry Stocks - dars.gov.et
HIND|Vyome Holdings Ord Shs|Price:2.060|Chg%:-0.080 - TradingKey
HIND|Vyome Holdings Ord Shs|Price:1.990|Chg%:-0.010 - TradingKey
Price to sales forward of Vyome Holdings, Inc. – NASDAQ:HIND - TradingView
Vyome Holdings Inc. (HIND) Q1 2026 Earnings: Narrower Loss Beats Expectations Amid Weak Revenue DisclosureGuidance Downgrade Alert - dars.gov.et
Vyome Holdings Inc. (HIND) Q1 2026 Earnings: EPS Beat Cuts Losses, but Stock Slides on Revenue Absence - dars.gov.et
Vyome (HIND) Proxy Filing Summary - Quartr
Vyome (HIND) Proxy filing Summary - Quartr
Vyome (HIND) Q4 2025 earnings summary - Quartr
Vyome (HIND) Q3 2025 earnings summary - Quartr
Vyome Holdings Inc. (HIND) Q1 2026 Earnings: Narrowing Losses Boost Investor ConfidenceRevenue Beat Analysis - dars.gov.et
Vyome Holdings (HIND) Slides 3.2% as Shares Test Key Support ZoneValue ETF - dars.gov.et
HIND Q1 2026 Earnings: Surprise EPS Beat Amidst No Revenue, Stock DeclinesEarnings Season Outlook - po-news-eg.net
Price to book forward of Vyome Holdings, Inc. – NASDAQ:HIND - TradingView
Vyome Holdings Inc. (HIND) Q1 2026 Earnings: EPS Surprise Beats Street EstimatesEBITDA Analysis - po-news-eg.net
HIND Q1 2026 Earnings: Narrower-than-Expected Loss Drives Stock HigherEPS Miss Report - DonanımHaber
Enterprise value to EBITDA forward of Vyome Holdings, Inc. – NASDAQ:HIND - TradingView
Vyome receives Chinese patent for acne treatment formulation - Investing.com
Vyome receives Chinese patent for acne treatment formulation By Investing.com - Investing.com Canada
Enterprise value to revenue forward of Vyome Holdings, Inc. – NASDAQ:HIND - TradingView
Number of shareholders of Vyome Holdings, Inc. – NASDAQ:HIND - TradingView
Vyome Holdings, Inc. Actuals & Estimates (NASDAQ:HIND) - TradingView
HIND Forecast — Price Target — Prediction for 2027 - TradingView
Vyome Holdings Inc. (HIND) Q1 2026 Earnings: Narrower-Than-Expected Loss Fails to Lift StockQuarterly Profit Report - dars.gov.et
ReShape Lifesciences Stock Rocketed 37% Today – Here’s Why - MSN
HIND Q1 2026 Earnings: EPS Surprises Positive as Cost Control Takes Center StageAnalyst Earnings Estimate - newsline.com
HIND Q1 2026 Earnings: EPS Surprises with 18.3% Beat Amid Revenue UncertaintyFiscal Year Earnings - newsline.com
Vyome Holdings (HIND) Declines 3.65% as Stock Tests Key Support ZoneIntraday Trade Ideas - dars.gov.et
HIND Q1 2026 Earnings: EPS Beats Estimates as Losses Narrow; Stock RisesCFO Commentary Report - newsline.com
Vyome to present VT-1953 Phase 2 data at cancer research meeting - Investing.com
Earnings call transcript: Vyome Holdings Q1 2026 shows strong cash position - Investing.com
HIND Q1 2026 Earnings: EPS Beats Estimates as Development Pipeline AdvancesSurprise Factor Analysis - The Legal Advocate
HIND Q1 2026 Earnings: EPS Surpasses Estimates as Company Advances PipelineROA Comparison - The Legal Advocate
Vyome Holdings reports Q1 2026: $8.8M cash, $10.2M total assets, net loss $986K - TradingView
HIND Q1 2026 Earnings: Narrower-than-expected loss per share boosts investor sentimentNon-GAAP Earnings - dars.gov.et
Press Release: Vyome Holdings Reports First Quarter 2026 Results With Key FDA Filings and Strong Balance Sheet - Moomoo
Vyome Holdings Reports First Quarter 2026 Results With Key FDA Filings and Strong Balance Sheet - BioSpace
HIND Q1 2026 Earnings: EPS Beats Estimates Despite Revenue AbsenceDownward Estimate Revision - The Legal Advocate
HIND - Finviz
HIND Q1 2026 Earnings: EPS Beat Despite Limited Revenue VisibilityEPS Consistency Score - The Legal Advocate
Vyome Holdings Inc. (HIND) Q4 2025 Earnings: Significant EPS Beat Highlights Cost DisciplineProfessional Trade Ideas - Newser
HIND News | VYOME HOLDINGS INC (NASDAQ:HIND) - ChartMill
Maxim Group Maintains Vyome Holdings(HIND.US) With Buy Rating, Maintains Target Price $15 - Moomoo
Finanzdaten der Vyome Holdings Inc-Aktie (HIND)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):